Thrombosis is a significant cause of death in a variety of diseases,and anticoagulation is the main method of thrombosis inhibition.Nevertheless,currently in clinical practice,the application of most commonly used anticoagulant drugs is limited due to the risk of bleeding,particularly for patients with atrial fibrillation who require long-term anticoagulant therapy.Therefore,it is necessary to explore and develop more effective and safer anticoagulant drugs.Researchers have studied the coagulation mechanism in depth and found that F Ⅺ/F Ⅺ a inhibitors have the potential to effectively inhibit coagulation without affecting physiological hemostasis.So far,a few clinical phase Ⅱ trials involving atrial fibrillation and other diseases(such as myocardial infarction,stroke,etc.)suggest that FⅪ/FⅪa inhibitors tend to have a lower bleeding risk than direct oral anticoagulants(DOACs),which requires further studies in clinical phase Ⅲ trials to verify their effectiveness and safety.Potentially,FⅪ/FⅪa inhibitors are expected to be a new option for anticoagulation.Based on clinical practice,the author will discuss the anticoagulation mechanism,research progress and application prospects of FⅪ/FⅪa inhibitors.
国家科技期刊平台
NSTL
万方数据
